Hints and tips:
Related Special Reports
...Leqembi slowed cognitive decline by 27 per cent compared with the placebo group in a phase 3 trial....
...Need to know: business Novo Nordisk announced a €1bn deal for a German biotech developing therapies to treat heart disease, as the Danish group seeks to branch out from its blockbuster diabetes and weight...
...Now, she said, the science was starting to evolve rapidly. “Despite advances in therapy, there really have been no cures for these diseases....
...It is also developing an intranasal migraine therapy, zavegepant....
...drugs and ensuring a pipeline of new therapies....
...Noom markets itself as a platform for sustainable weight loss through applying the psychological framework of cognitive behavioural therapy and offering one-to-one support from a health coach....
...The Alzheimer’s Association, an advocacy group, said the trial results were the “strongest” released to date for an amyloid-reducing drug and suggested an “inflection point” for treatment of the disease....
...Pfizer’s chief executive Albert Bourla said the pharma group was “deploying its financial resources to advance the battle against cancer”....
...The Capuchin Order’s proposal cites a 2021 study by I-Mak, a research group focusing on health inequity, which found Merck had filed 95 secondary patents on its cancer drug Keytruda....
...He said Pfizer had made great progress in oncology over the past decade, building what was a pipeline of only two or three molecules into one of the largest therapeutic areas in the group....
...“This would give us a foot in the door for treatments because ultimately down the road its going to take combination therapy to have a voilà kind of effect,” he said....
...That’s important for hiring and for health. But it’s about growing well.” Late to the party? Capital Group was years, if not decades, late to the ETF party....
...Besides Rallo and Boral, who worked together at Aegis Capital and Maxim Group, there’s Ben Piggott....
...Asked about the city’s prospects of luring big life sciences groups, he replied: “It’s a joke. It’s a joke . . . Regeneron is not coming to the city. Merck’s not coming to the city....
...Biogen priced it at $56,000 a year (since cut), alienating patient groups....
...Several other large US pharma groups, including Eli Lilly, AbbVie and Amgen have clinched similar agreements over the past two years as western drugmakers increasingly seek to license high-potential therapies...
...BioNTech is one of 17 groups to have proceeded to clinical evaluation of a Covid-19 vaccine, according to the World Health Organization....
...By switching to offer online classes and adding third-party apps in fields such as meditation, nutrition and therapy on to its platform, Gympass not only survived the global health crisis but emerged in...
...The US life sciences group said on Thursday it would acquire US-listed Acceleron for $180 per share in cash in a deal that is expected to close in the fourth quarter....
...The release of unexpectedly good trial results sent shares in the US pharma group soaring at the start of the month....
...Michael McDonnell, Biogen’s chief financial officer, said the Massachusetts-based drugmaker welcomed the formal review and that it would be “good for everyone involved to ensure confidence in the therapy...
...The bullish projections by Airfinity, a health data analytics group, suggest the two messenger RNA jab producers will control three-quarters of the non-Chinese Covid vaccine market in 2022....
...Merck, a $213bn company with a portfolio spanning human and animal health, is not alone in facing a patent cliff....
...Topol said the pills would not be a substitute for vaccines, since they would only offer protection for a few days after receiving the therapy....
...therapies....
International Edition